Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 5/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.33 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 6/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153613 | 1.00 | BRD4 (0.33) | BRD4MAPK7MAP3K5CSNK2A1IRAK4 | |
| SCHEMBL2144344 | 0.87 | BRD4 (0.34) | BRD4MAPK7MAP3K5IRAK4JAK2 | |
| SCHEMBL2144337 | 0.87 | BRD4 (0.34) | BRD4MAPK7MAP3K5IRAK4JAK2 | |
| SCHEMBL3301958 | 0.86 | JAK2 (0.37) | BRD4MAPK7MAP3K5IRAK4EML4 | |
| SCHEMBL3301970 | 0.86 | JAK2 (0.37) | BRD4MAPK7MAP3K5IRAK4EML4 | |
| SCHEMBL3303907 | 0.84 | BRD4 (0.37) | BRD4MAPK7MAP3K5CSNK2A1EML4 | |
| SCHEMBL3303909 | 0.84 | BRD4 (0.37) | BRD4MAPK7MAP3K5CSNK2A1EML4 | |
| SCHEMBL2144388 | 0.81 | MAP3K5 (0.38) | MAP3K5CSNK2A1IRAK4JAK2JAK3 | |
| SCHEMBL2144383 | 0.81 | MAP3K5 (0.38) | MAP3K5CSNK2A1IRAK4JAK2JAK3 | |
| SCHEMBL2144910 | 0.80 | JAK2 (0.43) | MAP3K5IRAK4JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | claimed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | claimed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | claimed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | claimed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | BRD4 596/4885MAPK7 195/4885MAP3K5 5/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | BRD4 596/4885MAPK7 195/4885MAP3K5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.